Table 8.
Post-hoc analysis of clinical trials on targeted and immunotherapy agents in melanoma: duration of intracranial response in brain metastases.
| Treatment | Molecular Subgroup | Brain Metastases | Intracranial Response Rate | Duration of Intracranial Response |
|---|---|---|---|---|
| Pembrolizumab [161] | None | Untreated | 26% | Not reported |
| Nivolumab [162] | None | Untreated | 20% | 2.5 months |
| Ipilimumab + Nivolumab [163] | None | Untreated | 54% | NR |
| Dabrafenib + Trametinib [164] | BRAF V600E mutant | Untreated | 58% | 6.5 months |
| Vemurafenib + Cobimetinib + Atezolizumab [165] | BRAF V600E mutant | Untreated | 42% | 7.4 months |